Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Sep 23, 2019 12:49pm

288 Views

Post# 30155224

RE:RE:RE:Biggest news Ever

"a Porsche. they will nail it. placebo showed 13% MACE cumulative patient event rate in Phase II and it was over 7 month treatment. now we have 27 months so placebo will definitely show higher than 13% . considering 15% only for Placebo population, this represents 0.15 x 2425 x 0.5 (assuming half placebo and half Betonmace) = 182 MACE events. they said they had 275 in total so this leave 93 for the Apabetalone population . this is a 50% reduction. they will smash the 30% required"

A like the excitement, but need to point out the limitations of this statement above. The post-hoc analyses were almost entirely comprised of the "softer" components of the 5-point MACE composite. There were very few 3-point MACE events (cardio death, non-fatal MI, non-fatal stroke) in the Phase 2s. I am assuming that the quoted the 13% placebo rate is the rate of 5-point MACE in the diabetic patients in the pooled Phase 2s. BETonMACE is all 3-point MACE. So just keep these things in mind when extrapolating from the Phase 2s to Phase 3 BETonMACE. Here's a couple past posts of mine that break this down in more detail:

https://agoracom.com/ir/Resverlogix/forums/discussion/topics/653975-5-point-vs-3-point-mace/messages/2052158

https://agoracom.com/ir/Resverlogix/forums/discussion/topics/706042-time-to-add-3-vs-5-pt-mace/messages/2189306

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale